News
NEO
8.05
-0.98%
-0.08
Insider Buying Surge: NeoGenomics Directors Make Bold Moves!
TipRanks · 1d ago
Earnings Scheduled For May 9, 2025
Benzinga · 2d ago
NeoGenomics CEO Makes Bold Stock Purchase!
TipRanks · 2d ago
A Look at NeoGenomics's Upcoming Earnings Report
Benzinga · 3d ago
NeoGenomics Directors Make Bold Moves with Major Stock Purchases
TipRanks · 3d ago
Assessing NeoGenomics: Insights From 9 Financial Analysts
Benzinga · 5d ago
NeoGenomics Is Maintained at Overweight by Piper Sandler
Dow Jones · 5d ago
NeoGenomics Price Target Cut to $12.00/Share From $18.00 by Piper Sandler
Dow Jones · 5d ago
Piper Sandler Maintains Overweight on NeoGenomics, Lowers Price Target to $12
Benzinga · 5d ago
It's Not Too Late to Jump on These Under-the-Radar Momentum Plays
NASDAQ · 5d ago
NeoGenomics price target lowered to $12 from $18 at Piper Sandler
TipRanks · 5d ago
Piper Sandler Keeps Their Buy Rating on NeoGenomics (NEO)
TipRanks · 5d ago
NEOGENOMICS INC <NEO.O>: PIPER SANDLER CUTS TARGET PRICE TO $12 FROM $18
Reuters · 5d ago
Weekly Report: what happened at NEO last week (0428-0502)?
Weekly Report · 6d ago
3 Small-Cap Stocks Walking a Fine Line
Barchart · 6d ago
NeoGenomics, Sherwin-Williams, Grab, Paccar, First Solar: Trending by Analysts
TipRanks · 05/03 09:02
NeoGenomics Price Target Cut to $10.00/Share From $17.00 by Morgan Stanley
Dow Jones · 05/01 17:45
NeoGenomics Is Maintained at Equal-Weight by Morgan Stanley
Dow Jones · 05/01 17:45
Morgan Stanley Maintains Equal-Weight on NeoGenomics, Lowers Price Target to $10
Benzinga · 05/01 17:34
NeoGenomics Pays Off 1.25% Convertible Senior Notes
Barchart · 05/01 06:05
More
Webull provides a variety of real-time NEO stock news. You can receive the latest news about Neogenomics Inc through multiple platforms. This information may help you make smarter investment decisions.
About NEO
More
NeoGenomics, Inc. is a cancer diagnostics company specializing in cancer genetics testing and information services. The Company offers comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with diagnostic and predictive testing to help them diagnose and treat cancer. Its services include clinical cancer testing; interpretation and consultative services; molecular and NGS testing; comprehensive technical and professional services offering; clinical trials and research; validation laboratory services, and oncology data solutions. It operates a network of laboratories for full-service sample processing and analysis services throughout the United States and a full-service sample-processing laboratory in Cambridge, United Kingdom. Its testing services include Cytogenetics (karyotype analysis), Fluorescence In-Situ Hybridization (FISH), Flow cytometry, and others.